SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID-19 pandemic: a double-blind, randomised, placebo-controlled trial.

Merete B LongHani Abo-LeyahYan Hui GiamThenmalar VadivelooRebecca C HullHolly R KeirThomas PembridgeDaniela Alferes De LimaLilia DelgadoSarah K InglisChloe HughesAmy GilmourMarek GierlinskiBenjamin J M NewGraeme MacLennanAlbena T Dinkova-KostovaJames D Chalmers

Published in: ERJ open research (2024)

SFX-01 treatment did not improve clinical status or modulate key Nrf2 targets in patients with CAP primarily due to SARS-CoV-2 infection.

Keyphrases

community acquired pneumonia
double blind
clinical trial
study protocol
open label
oxidative stress
placebo controlled
combination therapy
sars cov